FDA 483 OBSERVATION · #24 OF 1,945 MOST-CITED

Record keeping

FDA cited this observation 804 times across 754 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Veterinary Medicine804
BY FISCAL YEAR
FY20271
FY202636
FY202537
FY202438
FY202346
FY202237
FY202111
FY202039
FY2019114
FY2018118
FY2017139
FY2016188

What this observation means, and how to comply

SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.

21 CFR 820.180 (devices) · 21 CFR 211.180 (drugs)

21 CFR 820.180 (General requirements (records)) is a Quality System Regulation section; since QMSR took effect on 2 February 2026 FDA inspects this as “Control of Documents and Records”: 21 CFR 820.35 and 820.45, and ISO 13485 clauses 4.2.1, 4.2.4 and 4.2.5 (CP 7382.850 Attachment A).

Required records were not maintained, were incomplete, or were not retained, retrievable, and legible for the required period — the general recordkeeping failures that undermine the ability to reconstruct what was done.

Why FDA writes it — Records are the evidence that controls were actually applied. If records are missing, incomplete, or unretrievable, the firm cannot demonstrate compliance for any activity they should document — so recordkeeping failures both stand alone and compound every other finding.

HOW TO COMPLY
  • Maintain all required records so they are legible, retrievable, and stored to minimise deterioration and loss, for the required retention period.
  • Make records available for review and copying by FDA during inspection.
  • Ensure records are complete and made at the time of the activity (contemporaneous), not reconstructed.
  • Control record changes with attribution, date, and reason — never obscure an original entry.
WHY FIRMS GET CITED
  • Records completed after the fact or in batches, breaking contemporaneity.
  • Poor storage/retrieval so records exist but cannot be produced during inspection — read as “no record”.
PROFESSIONAL · REMEDIATION PLAYBOOK · SPEQ SYNTHESIS

How to close this finding — and stop it recurring

CHECKING ACCESS

Checking your access…

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 0.7× the rate of the average FDA-cited firm (5.7% vs 7.8%), across 754 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

You did not maintain complete treatment records.

Meadowood Dairy · Turner, Oregon · Veterinary Medicine · 2026-10-14

You did not keep treatment records.

Scott Bone · Calhoun, Georgia · Veterinary Medicine · 2026-09-22

You did not maintain complete treatment records.

Getz-Milk Dairy, LLC · Wilson, Michigan · Veterinary Medicine · 2026-09-17

You did not maintain complete treatment records.

Moxee Dairy, LLC · Moxee, Washington · Veterinary Medicine · 2026-09-09

You did not maintain complete treatment records.

A&M DeSousa Dairy · Turlock, California · Veterinary Medicine · 2026-08-06

You did not maintain complete and retain treatment records.

Kevin Kirby · North Bloomfield, Ohio · Veterinary Medicine · 2026-08-06

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Data integrity (ALCOA+) →Veterinary industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →